Neuronano update august 2013

neuronano pharmaCompany and operational activities

-9oUL\YV

© 2013 Neuro10-9 Pharma, Inc. All rights reserved.

Company overview and business model

-9oUL\YV


>L�HYL�H�MVY�WYVÄ[�WOHYTHJL\[PJHS�JVTWHU`�KL]LSVWPUN�HUK�JVTTLYJPHSPaPUN�UHUVTLKPJPULZ�MVY�[OL�[YLH[TLU[�VM�[OL�Z\I�VW[PTHSS`�HKKYLZZLK�VY�WYLZLU[S`�PUJ\YHISL�diseases.

ACADEMIA INDUSTRY

-9oUL\YV WV[LU[PHS�WHY[ULYZ

(JHKLTPH�PUK\Z[Y`�WHY[ULY�Z`UKPJH[L�MVY�HK]HUJLTLU[�VM�WSH[MVYT�[LJOUVSVNPLZ�PU[V�KY\N�JHUKPKH[LZ��

6\Y�Z[YH[LN`��JH[JOPUN�[OL�THYRL[�YLSL]HUJL�^H]L

-9oUL\YV


7YLJSPUPJHS�9LZLHYJO�

7YLJSPUPJHS�+L]LSVWTLU[�

*SPUPJHS�9LZLHYJO

(JHKLT

PJ�WHY[U

LYZ

0UK\Z[Y`

�WHY[ULY

Z

5L\YV5

HUV�7OH

YTH�2L`

�(J[P]P[P

LZ

4HYRL[,_P[

ROI

��RT�O�

��RT�O�

4HYRL[�9LSL]HUJL�>H]L

¸>H]LZ¹�[V�*VTTLYJPHSPaH[PVU

6\Y�Z[YH[LNPJ�NVHS

-9oUL\YV


ACADEMIA INDUSTRY

commerciability

inno

vatio

n

MAR

KET

idea

platform concept

platform technology

lead compounds

drug candidatedrug

-9oneuro

6\Y�L_[LUKLK�[LHT�

-9oUL\YV


Co-founder &

lead inventor

Kabanov

Co-founder &

acting CEO

Gaymalov

7YPUJPWHS�ZJPLU[PZ[Z�(for

each plafrom

technology)

Yi BatrakovaManickam

Board of KPYLJ[VYZ

Kabanov Polinsky RomarMalkov

Board of advisors

Banks FarrellMcCall Zalipsky

Alakhova

=PJL�7YLZPKLU[�for BD &

Licensing

De Ridder

Bloom

6\Y�VWLYH[PVUZ

-9oUL\YV


4+ delivery platforms20+ lead compounds10+ indications

Academia

Industry key activities

ReCoPE: reverse concept.

product engineeriing

IP generation

& management

business development -

partnering & licensing

securing grants

& equity investment

translational research key outcomes

Spin-off portfolio

companies

Partnerships

Out-licensing deals

-9oneur

o

Lean :OHYLK�HUK�SV^LYLK�YPZR *HWP[HSPaPUN�VU�LZ[HISPZOLK�HUK�LTLYNPUN�YLZV\YJLZ�PU�5*

6\Y�JVYL�[LJOUVSVNPJHS�HZZL[Z

-9oUL\YV


pluroMAC™Platform Delivery Technology

Binary:\WLYHJ[P]LPLD™Platform Delivery Technology

nanoZYME™Platform Delivery Technology

*LSS�4LKPH[LK�DeliveryTechnology

Macromolecules

Small molecules

Macromolecules

Small molecules

Antibodies Genes

��WYVK\J[�JHUKPKH[LZ 12+ disease models ��WH[LU[Z�HWWSPJH[PVUZ


-9oUL\YV


LUa`TLZ! SOD *H[HSHZL OPH BCHEHRP

3LW[PU

7HJSP[H_LS�

Doxoru-IPJPU�

BDNF

OVYTVULZ!

J`[VRPULZ!

��WOHYTHJL\[PJHS�SLHK�JVTWV\UKZ!

��IPVWOHYTHJL\[PJHS�SLHK�JVTWV\UKZ!

6\Y�J\YYLU[�WPWLSPUL

-9oUL\YV


NNP-bdnfNZ Rett syndrome

UveitisNNP-sodNZ

NNP-sodNZ Amyotrophic

lateral sclerosis

leptiPOL-LM Obesity

Discovery CandidateSelection

Pre-clinicalResearch

Pre-clinical Development

Clinical Phase 1,2Product Indications

CancerNNP-D773c 505(b)(2)

leptiPOL-HM Alzheimer's disease


-9oUL\YV


pluroMAC™Platform Delivery Technology

Binary:\WLYHJ[P]LPLD™Platform Delivery Technology

nanoZYME™Platform Delivery Technology

*LSS�4LKPH[LK�DeliveryTechnology

Macromolecules

Small molecules

Macromolecules

Small molecules

Antibodies Genes

��WYVK\J[�JHUKPKH[LZ 12+ disease models ��WH[LU[Z�HWWSPJH[PVUZ

June 18, 2013;OL�(TLYPJHU�4LKPJHS�(ZZVJPH[PVU�OHZ�VMÄJPHS-ly recognized obesity as a disease, a move

that could induce WO`ZPJPHUZ� [V� WH`�TVYL�H[[LU[PVU� and ZW\Y� TVYL� PUZ\YLYZ� [V� WH`�MVY�[YLH[TLU[Z.

��6ILZP[`�PUKPJH[PVU��V]LY]PL^

-9oUL\YV


6ILZP[`��KPZLHZL�VY�JVUKP[PVU&�

6ILZP[`��VUL�VM�[OL�IPNNLZ[�WV[LU[PHS�NSVIHS�THYRL[Z�

US EU

17%32%

6ILZP[`�[YLH[TLU[�JOHSSLUNL

<UTL[�ULLK

In obese patients, the transport of

gut hormones to the brain is impaired

(gut hormone desensitization)

Its possible to treat obesity by de-

livering gut hormones directly to the

brain and restore natural sensitivity

to the hormone observed in health

people.

,MMLJ[P]L�HUK�ZHML�KLSP]LY`�VM�N\[�OVYTVULZ�HJYVZZ�ISVVK�IYHPU�IHYYPLY

��6ILZP[`�PUKPJH[PVU��(70��[LJOUVSVN`�HUK�WYVK\J[

-9oUL\YV


group of hormones secreted by enteroendocrine cells in the stomach,

pancreas, and small intestine that play a role of neurotransmitters

and neuromodulators in the central and peripheral nervous systems.

(J[P]L�WOHYTHJL\[PJHS�PUNYLKPLU[Z

+LSP]LY`�WSH[MVYT�[LJOUVSVN`��WS\YV4(* 7YVK\J[�7YV[V[`WL��SLW[P763�34�

Macro-molecules

;LJOUVSVN`� PU]VS]LZ� Z\YMHJL� TVKPÄJH[PVU� VM� [OLYHWL\[PJ� WYV[LPUZ�with precisely crafted poloxamers and allows active delivery of these

WYV[LPUZ�[V�[OL�KLÄULK�IYHPU�YLNPVUZ�

SLW[P763�34��HK]HU[HNLZ!�� Rapid brain delivery

�� Targeted hypothalamus delivery

�� Immediate effectiveness

�� Independence of diet and exercise

�� Convenience of intranasal delivery

�� Safety

SLW[P763�34�!�Poloxamer conjugated leptin hormone for intranasal

and intravenous hypothalamus delivery

SLW[PU GLP-1 amylin OXM

50/�MVY�:;;9�7OHZL�0�00;YLH[PUN�6ILZP[`�^P[O�0U[YHUHZHS�3LW[PU�(UHSVNZ��$1,150,000 7LUKPUN

��6ILZP[`�PUKPJH[PVU��VWLYH[PVUHS�HJ[P]P[PLZ

-9oUL\YV


-\UK�YHPZPUN�HJ[P]P[PLZ!

7\ISPJH[PVUZ�PU�SLHKPUN�WLLY�YL]PL^LK�QV\YUHSZ

*VSSHIVYH[PVUZ

07�HZZL[Z

�� Dr. William A. )HURZ, M.D. <UP]LYZP[`�VM�>HZOPUN[VU�� Dr. Susan A. Farr, Ph.D. :HPU[�3V\PZ�<UP]LYZP[`�� Dr. Andrew :^PJR, Ph.D. <5*�5\[YP[PVU�9LZLHYJO�0UZ[P[\[L

�� Tong et al. (2012). Mol Pharm. 10:360-77

�� Tong et al. (2010). Mol Pharm 7:984-92

�� Price et al. (2010). 1�7OHYTHJVS�,_W�;OLY�333:253-63

�� Batrakova et al. (2008). )PVJVUQ\N�*OLT 19:1071-7

�� Batrakova et al (2005). )PVJVUQ\N�*OLT 16:793-802

UNC - NIH RO17VS`WLW[PKL�4VKPÄJH[PVU�MVY�,UOHUJLK�)YHPU�+LSP]LY`��$1,920,000 (J[P]L

(JHKLTPJ�JVSSHIVYH[PVUZ!

0UK\Z[Y`�JVSSHIVYH[PVUZ!�� Dr. Catherine Farrell, Ph.D. 0UKLWLUKLU[�JVUZ\S[PUN (Amgen)

�� Dr. John 6NLa, Ph.D. 7LHR�[V�7LHR�)PV+L]LSVWTLU[ (Amgen)

�� Dr. David Essayan, M.D. 6UJVYK��0UJ (Amgen)

�� Dr. Samuel AHSPWZR`, Ph.D. SJZ (ALZA)

�� Dr. John McCall, Ph.D. 7OHYTHJ��33*��7ÄaLY�

1 issued, ��WLUKPUNWH[LU[Z

��*HUJLY�PUKPJH[PVU��V]LY]PL^

-9oUL\YV


-VJ\Z�JHUJLY�PUKPJH[PVUZ

.SVIHS�PUJPKLUJL�KLH[OZ�]Z�UL^�JHZLZ��PU�TPSSPVUZ��

4VZ[�HK]HUJLK�KY\NZ��SPWVZVTHS�JOLTV[OLYHWPLZ

<UTL[�ULLK

5 yearsurvival

45%

V]HYPHU�JHUJLY

0

5 yearsurvival

5 yearsurvival

IYLHZ[�JHUJLY

15%93%

IV

2008

2030

7.6 12.7

13.2 22.2

5 yearsurvival

5 yearsurvival

68% 68%

T\S[PWSL�T`LSVTH RHWVZP�ZHYJVTH

;YLH[TLU[�HK]HU[HNLZ�� rapid API internalization

�� low immunogenicity

�� improved solubility

�� enhanced biocompatibility

�� increased bioavailability

�� superior API protection

(70�YLSLHZL�MYVT�SPWVZVTLZ�\WVU�HYYP]HS�PU[V�[OL�[\TVY

7LUL[YH[PVU�VM�(70�PU[V�[OL�[\TVY�JVYLZ

1

2

*\YYLU[S` IdeallyKY\N�YLSHZL

KY\N�KPMM\ZPVU

This group of possible APIs includes emulsions, micellar solutions,

liposomes, lipid nanoparticles, and drug-lipid conjugates.

��*HUJLY�PUKPJH[PVU��(70��[LJOUVSVN`�HUK�WYVK\J[

-9oUL\YV



+LSP]LY`�WSH[MVYT�[LJOUVSVN`��IPUHY`�ZH73? 7YVK\J[�7YV[V[`WL��557�+��J�MVY�73+

liposomal chemotherapies adjuvation with poloxamers

liposomal chemotherapies

:[LW��3PWVZVTHS�(70�JOLTV[OLYHW` :[LW��4L[H�HKQ\]H[PVU�^P[O�557�73+��

7YVSVUNLK�(70�OHSM�SPML

7YLMLYLU[PHS�[\TVY�WLUL[YH[PVU

Low serum levels of free API

,MÄJPLU[�(70�YLSLHZL�H[�ZP[L

,UOHUJLK�(70�WLUL[YH[PVU

0TWYV]LK�(70�LMÄJHJ`

6]LYJVTPUN�KY\N�YLZPZ[HUJL

Tumor

Liposomal drug at

the tumor site

Drug release from liposomes

and penetration into tumor site

��*HUJLY�PUKPJH[PVU��VWLYH[PVUHS�HJ[P]P[PLZ

-9oUL\YV


UNC Carolina CCNE$55,000(J[P]L



*VSSHIVYH[PVUZ

07�HZZL[Z

�� Dr. William Zamboni, PhD. UNC Chapel Hill�� Dr. Victoria Bae-Jump. M.D., PhD., UNC Chapel Hill�� Dr. David Darr, PhD., UNC Chapel Hill�� Dr. Charles Perou, PhD., UNC Chapel Hill�� Dr. Gabriel 3VWLa, M.D., PhD., 4+�(UKLYZVU�*HUJLY�*LU[LY�� Dr. Bulent 6aWVSH[, M.D., PhD., 4+�(UKLYZVU�*HUJLY�*LU[LY

Zhao et al., (2013)�1V\YUHS�VM�JVU[YVSSLK�YLSLHZL��!��


0UK\Z[Y`�JVSSHIVYH[PVUZ!�� Dr. Jo *H[V, Ph.D. *H[V�=LU[\YLZ

�� Dr. Ken Phelps, Ph.D. *HTHYNV�7OHYTHJL\[PJHS�:LY]PJLZ

UNC Carolina CNPP$20,000(J[P]L

4+�(UKLYZVU�*HUJLY�*LU[LY�**5,$55,000(J[P]L

UNC LCCC UCRF$100,0007LUKPUN

��WLUKPUNWH[LU[Z

��<]LP[PZ�PUKPJH[PVU��V]LY]PL^

-9oUL\YV


<]LP[PZ

<]LP[PZ�PZ�H��YK�SLHKPUN�JH\ZL�MVY�ISPUKULZZ�PU�<:

<UTL[�ULLK

7YVWVZLK�:VS\[PVU

9LHJ[P]L�V_`NLU�ZWLJPLZ��96:��

<]LP[PZ�PZ�Z^LSSPUN�HUK�PYYP[H[PVU�VM�[OL�\]LH��[OL�TPKKSL�SH`LY�VM�[OL�L`L��Uveitis requires an urgent referral and thorough

examination by an ophthalmologist or optometrist—HUK�\YNLU[�[YLH[TLU[�[V�JVU[YVS�[OL�PUÅHTTH[PVU�

��\]LP[PZ

BlindnesJH\ZLZ

USWVW\SH[PVU2.3 millioin people

PU�<UP[LZ�:[H[LZ�Z\MMLY�MYVT�\]LP[PZ

7YV�PUÅHTTH[VY`�JLSSZ�PUÄS[YH[PUN�Z[PT\SH[LK�ZP[LZ��PUK\JPUN�[OL�96:�production and accumulation. This leads to the oxidative stress, cell

death, and ultimately blindness.

7YV�PUÅHTTH[VY`�JLSSZ

ROS

96:�ZJH]LUNLY�LUa`TLZ

96:�JVU]LY[LK�[V�V_`NLU�NHZ�HUK�^H[LY

ROS scavenger enzymes are aimed to reduces the hypoxic stress

HUK�[V_PJP[`�K\YPUN�OHYTM\S�JOYVUPJ�PUÅHTTH[PVU

��<]LP[PZ�PUKPJH[PVU��(70��[LJOUVSVN`�HUK�WYVK\J[

-9oUL\YV



7YVK\J[�7YV[V[`WL��:6+�UHUVA@4,

SOD *H[HSHZL

:\WLYV_PKL�KPZT\[HZLZ�LUJHNLK�PU�WVS`TLY�ZOLSM

��<]LP[PZ�PUKPJH[PVU��VWLYH[PVUHS�HJ[P]P[PLZ

-9oUL\YV


'�4:<�-\UKLK�I`�9\ZZPHU�4LNHNYHU[��(J[P]L



*VSSHIVYH[PVUZ

07�HZZL[Z

�� pending

�� in preparation

��WH[LU[Z�ÄSLK

��(SaOLPTLY»Z�+PZLHZL�PUKPJH[PVU��V]LY]PL^

-9oUL\YV


(SaOLPTLY»Z�+PZLHZL

(+�HJJV\U[Z�MVY��[V��WLYJLU[�VM�KLTLU[PH�JHZLZ

;OLYL�PZ�UV�J\YL�MVY�[OL�(SaOLPTLY»Z�KPZLHZL��^OPJO�^VYZLUZ�HZ�P[�WYVNYLZZLZ��HUK�L]LU[\HSS`�SLHKZ�[V�KLH[O�

(+�WVW\SH[PVU�HJYVZZ�[OL��THQVY�

THYRL[Z13M people

US 4.3M

JP 2.5M

UK 1.2MSP 0.8M

IT 1.3M

GR 1.6M

FR 1.1M

NLULYHS�WYL]HSLUJL�YH[L��VM�[V[HS�WVW\SH[PVU

(SaOLPTLY»Z�KPZLHZL�[YLH[TLU[�JOHSSLUNL

<UTL[�ULLK

In AD patients, the transport of leptin

to the brain is impaired.

Its possible to slow down the degen-

erative process of AD by delivering

SLW[PU�KPYLJ[S`�[V�[OL�IYHPU��ZWLJPÄJHS-ly to hippocampus.

,MMLJ[P]L�HUK�ZHML�KLSP]LY`�VM�[OL�SLW[PU�OVYTVUL�HJYVZZ�ISVVK�IYHPU�IHYYPLY�[V�[OL�OPWWVJHTW\Z

��(+�PUKPJH[PVU��(70��[LJOUVSVN`�HUK�WYVK\J[

-9oUL\YV


Leptin is a 16-kDa protein

hormone that plays a key role

in regulating energy intake

and expenditure, including

appetite and hunger,

metabolism, and behavior.

(J[P]L�WOHYTHJL\[PJHS�PUNYLKPLU[

+LSP]LY`�WSH[MVYT�[LJOUVSVN`��WS\YV4(* 7YVK\J[�7YV[V[`WL��SLW[P763�/4��

Macromolecules

;LJOUVSVN`� PU]VS]LZ� Z\YMHJL� TVKPÄJH[PVU� VM� [OLYHWL\[PJ� WYV[LPUZ�with precisely crafted poloxamers and allows active delivery of these

WYV[LPUZ�[V�[OL�KLÄULK�IYHPU�YLNPVUZ�

SLW[P763�/4��HK]HU[HNLZ!�� Rapid brain delivery

�� Targeted hippocampus delivery

�� Immediate effectiveness

�� Convenience of intranasal delivery

�� Safety

SLW[P763�/4�!�Poloxamer conjugated leptin hormone for�PU[YHUHZHS�OPWWVJHTW\Z��KLSP]LY`

SLW[PU

��(+�PUKPJH[PVU��VWLYH[PVUHS�HJ[P]P[PLZ

-9oUL\YV


<5*��<>��50/�;YHUZSH[PVUHS�<6�$7,500,000 7LUKPUN



*VSSHIVYH[PVUZ

07�HZZL[Z

�� Dr. William A. )HURZ, M.D. <UP]LYZP[`�VM�>HZOPUN[VU�� Dr. Susan A. Farr, Ph.D. :HPU[�3V\PZ�<UP]LYZP[`�� Dr. Andrew :^PJR, Ph.D. <5*�5\[YP[PVU�9LZLHYJO�0UZ[P[\[L

�� In preapration


0UK\Z[Y`�JVSSHIVYH[PVUZ!�� Dr. Catherine Farrell, Ph.D. 0UKLWLUKLU[�JVUZ\S[PUN (Amgen)

�� Dr. John 6NLa, Ph.D. 7LHR�[V�7LHR�)PV+L]LSVWTLU[ (Amgen)

�� Dr. David Essayan, M.D. 6UJVYK��0UJ (Amgen)

�� Dr. Samuel AHSPWZR`, Ph.D. SJZ (ALZA)

�� Dr. John McCall, Ph.D. 7OHYTHJ��33*��7ÄaLY�

��WH[LU[�WLUKPUN

��(T`V[YVWOPJ�SH[LYHS�ZJSLYVZPZ�PUKPJH[PVU��V]LY]PL^

-9oUL\YV


(T`V[YVWOPJ�SH[LYHS�ZJSLYVZPZ

(3:�WH[PLU[Z�H]LYHNL�Z\Y]P]HS�[PTL��`LHYZ

(3:�PZ�H�WYVNYLZZP]L�UL\YVKLNLULYH[P]L�KPZLHZL�[OH[�HMMLJ[Z�TV[VY�UL\YVUZ��[OL�ULY]LZ�^OPJO�JVTT\UPJH[L�^P[O�T\ZJSLZ�[OYV\NOV\[�[OL�IVK �̀�HYL�WYVNYLZZP]LS`�KLZ[YV`LK�

(3:�[YLH[TLU[�JOHSSLUNL

<UTL[�ULLK

:HML�HUK�LMMLJ[P]L�KLSP]LY`�VM�UH[\YHS�HU[PV_PKHU[�LUa`TLZ�[V�H[[LU\H[L�V_PKH[P]L�KHTHNL�PU�IV[O�MHTPSPHS�HUK�ZWVYHKPJ�(3:�WH[PLU[Z�

[OLYL�HYL40,000 ALS JHZLZ�PU�<:

[OLYL�HYL200,000 ALS

JHZLZ�PU�YLZ[�VM�[OL�^VYSK

The standard of care therapy, Riluzole is modestly-effective and

does not cure ALS. It decreases glutamate-induced excitotoxicity

and extends patient survival by only 3-6 months while they need to

be continuously monitored for possible liver toxicity. There is an \YNLU[�ULLK�[V�KL]LSVW�H�ZHML�HUK�LMMLJ[P]L�[OLYHW`�MVY�(3:��

��(3:�PUKPJH[PVU��(70��[LJOUVSVN`�HUK�WYVK\J[

-9oUL\YV


7YVK\J[�7YV[V[`WL


+LSP]LY`�WSH[MVYT�[LJOUVSVN`��UHUVa`TL

Macromolecules

Small molecules

SOD

557�ZVK5A!� SOD enzyme encaged in nanoZYME with extended

half-life for�LUOHUJLK�PU[YHUHZHS�KLSP]LY`�[V�[OL�IYHPU

��(3:�PUKPJH[PVU��VWLYH[PVUHS�HJ[P]P[PLZ

-9oUL\YV


<5*��5*�;YH*:�7PSV[�7YVNYHT��$50,000 7LUKPUN



*VSSHIVYH[PVUZ

07�HZZL[Z

�� Dr. Carol 4PSSPNHU, Ph.D. >HRL�-VYLZ[�<UP]LYZP[ �̀�5*

�� Rosenbaugh et al. )PVTH[LYPHSZ. 2010 Jul;31(19):5218-26.

�� Klyachko et al. 5HUVTLKPJPUL. 2012 Jan;8(1):119-29

�� Manickam et al. 1�*VU[YVS�9LSLHZL. 2012 Sep 28;162(3):636-45

�� Rosenbaugh et al. (T�1�7O`ZPVS�9LN\S�0U[LNY�*VTW�7O`ZPVS��2013 Jun

1:R917-28

*+497�(T`V[YVWOPJ�3H[LYHS�:JSLYVZPZ�9LZLHYJO�7YVNYHT��(3:�;OLYHWL\[PJ�0KLH�(^HYK�$400,000 7LUKPUN


0UK\Z[Y`�JVSSHIVYH[PVUZ!�� Dr. John McCall, Ph.D. 7OHYTHJ��33*��7ÄaLY�

��WH[LU[Z�WLUKPUN

��9L[[�ZÙKYVTL�PUKPJH[PVU��V]LY]PL^

-9oUL\YV


9L[[�ZÙKYVTL

9L[[�ZÙKYVTL�PZ�H�UL\YVKL]LSVWTLU[HS�KPZVYKLY�VM�[OL�NYL`�TH[[LY�VM�[OL�IYHPU��0U�� P[�^HZ�KLTVUZ[YH[LK�[OH[�9L[[�ZÙKYVTL�PZ�JH\ZLK�I`�T\[H[PVUZ�PU�[OL�NLUL�4,*7��

9L[[�ZÙKYVTL�[YLH[TLU[�JOHSSLUNL

<UTL[�ULLK

Effective and safe delivery of BDNF

and other pleotrophic factors to the

brain will ameliorate Rett Syndrome

symptoms. However BDNF has L_[YLTLS`�ZOVY[�OHSM�SPML�HUK�WVVY�WLUL[YH[PVU�[OYV\NO�)))��

Rett syndrome (RTT) is an X-linked postnatal neurodevelopmental

disorder, which is primarily caused by mutations in the gene

encoding methyl-CpG binding protein 2 (MeCP2). A number

VM�4L*7��[HYNL[�NLULZ�OH]L�ILLU�PKLU[PÄLK��PUJS\KPUN�[OL�neurotrophic factor BDNF. 0[�OH]L�ILLU�ZOVÛ�[OH[�)+5-�V]LYL_WYLZZPVU�L_[LUKLK�[OL�SPMLZWHU��YLZJ\LK�H�SVJVTV[VY�KLMLJ[��HUK�YL]LYZLK�HU�LSLJ[YVWO`ZPVSVNPJHS�KLÄJP[�VIZLY]LK�PU�4LJW��T\[HU[Z�

��9L[[�Z`UKYVTL��(70��[LJOUVSVN`�HUK�WYVK\J[

-9oUL\YV


a secreted protein (cytokine)

that, in humans, is encoded

by the BDNF gene.

(J[P]L�WOHYTHJL\[PJHS�PUNYLKPLU[

7YVK\J[�7YV[V[`WL557�IKUM5A!�BDNF cytokine encaged in nanoZYME with extended

half-life for�LUOHUJLK�PU[YHUHZHS�KLSP]LY`�[V�[OL�IYHPU

Brain-derived UL\YV[YVWOPJ�MHJ[VY

+LSP]LY`�WSH[MVYT�[LJOUVSVN`��UHUVa`TL

Macromolecules

Small molecules

��9L[[�Z`UKYVTL�PUKPJH[PVU��VWLYH[PVUHS�HJ[P]P[PLZ

-9oUL\YV


5*�;YH*:�;YHUZSH[PVUHS�9LZLHYJO�4H[JOLK�7PSV[�.YHU[$50,000 7LUKPUN


*VSSHIVYH[PVUZ

07�HZZL[Z

�� Dr. William A. )HURZ, M.D. <UP]LYZP[`�VM�>HZOPUN[VU�� Dr. Steven Gray, Ph.D. UNC Chapel Hill

0U[LYUH[PVUHS�9L[[�:`UKYVTL�-\UKH[PVU��/LSW�(JJLSLYH[L�9L[[�;OLYHWL\[PJZ$150,000 7LUKPUN


0UK\Z[Y`�JVSSHIVYH[PVUZ!�� Dr. John McCall, Ph.D. 7OHYTHJ��33*��7ÄaLY�

��WH[LU[Z�WLUKPUN

8\LZ[PVUZ&

-9oUL\YV


*VU[HJ[�<Z�Zagit Gaymalov, Ph.D.

919.923.7401

[email protected]

Neuronano update august 2013

Documents

Transcript of Neuronano update august 2013